Dianthus Therapeutics Q1 EPS $(0.54) Misses $(0.44) Estimate, Sales $874.00K Beat $460.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Dianthus Therapeutics reported Q1 EPS of $(0.54), missing the $(0.44) estimate, but their sales of $874.00K exceeded the $460.00K estimate.
May 09, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Dianthus Therapeutics reported a Q1 EPS of $(0.54), missing estimates, but sales of $874.00K exceeded expectations.
The missed EPS estimate could negatively impact investor sentiment, while the significant beat on sales could offset some of the negative impact. The mixed results present a neutral short-term outlook for DNTH's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100